A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Her 2 Positive Breast Cancer|Breast Cancer Female|Breast Cancer Metastatic
Interventions: DRUG: Sacituzumab Govitecan|DRUG: Trastuzumab|DRUG: Trastuzumab and Hyaluronidase-oysk
Sponsor: Adrienne G. Waks
Collaborators: Gilead Sciences